For further news and related information, please visit the DuoCort Newsdesk here.
|
|
Tisdag, 22 Juni 2010 |
|
Helsingborg - Det svenska läkemedelsföretaget
DuoCort Pharmas nya mer fysiologiska behandling för binjurebarksvikt förbättrar
patienternas livskvalitet. Företaget presenterar dessa nya data från sin fas
II/III studie vid den 92:a årliga kongressen ENDO i San Diego.
|
|
Read more...
|
|
|
Måndag, 21 Juni 2010 |
|
Helsingborg / San
Diego - DuoCort Pharma´s new physiological treatment
for adrenal insufficiency improves patients' quality of life. The Swedish
pharmaceutical company presents new data from its phase II/III trial at the 92nd
annual ENDO congress in San Diego today.
|
|
Read more...
|
|
|
Onsdag, 16 Juni 2010 |
Helsingborg - Det svenska läkemedelsföretaget DuoCort Pharma tar
ytterligare ett steg närmare marknaden genom att ansöka om
marknadsgodkännande inom EU för sin nya behandling för den ovanliga och
livshotande sjukdomen binjurebarksvikt, ofta kallad Addisons sjukdom.
|
|
Read more...
|
|
|
Onsdag, 16 Juni 2010 |
|
Helsingborg - The Swedish speciality pharma company
DuoCort Pharma takes a step closer to the market by applying for market
authorisation in EU for its new treatment for the rare and life
threatening
disease adrenal insufficiency, often referred to as Addison´s disease.
|
|
Read more...
|
|
|
Lördag, 07 November 2009 |
|
European Life Science, autumn edition, features an article about DuoCort. Read it here.
|
|
|
Onsdag, 01 Juli 2009 |
PULS’s Head of Business Development, Maria Forss, is one of the 200 women selected by Maud Olofsson, the Minister for Enterprise and Energy and Deputy Prime Minister, in collaboration with ALMI Företagspartner, to participate in the Styrelsekraft program. This is a national mentoring program targeting qualified and experienced women who have the ambition to be board members of both private and public companies.
|
|
Read more...
|
|
|
Tisdag, 30 Juni 2009 |
|
Helsingborg Sweden June 29th 2009 - DuoCort publishes data
from its Phase I study for the rare and life threatening disease
adrenal insufficiency. The release profile of DuoCort’s new form of
treatment with once-a-day hydrocortisone dosing closely resembles the
physiological secretion pattern. The data is published today in the European Journal of Endocrinology , a leading scientific journal for endocrinology.
|
|
Read more...
|
|
|
Fredag, 12 Juni 2009 |
|
Helsingborg Sweden/Washington DC June 12th 2009 DuoCort gained promising data from its Phase II/III study for the rare and life threatening disease adrenal insufficiency. DuoCort’s new form of physiological treatment with once-a-day hydrocortisone dosing show improved cardiovascular and metabolic measures compared to standard hydrocortisone tablets given thrice daily. The company presents the data at the 91st annual ENDO congress in Washington DC.
|
|
Read more...
|
|
|
Måndag, 22 September 2008 |
Stanko Skrtic, Chief Scientific Officer, and Maria Forss, Head of business development, joined the PULS team of life sciences project management and drug development experts in mid August.
|
|
Read more...
|
|
|
Fredag, 27 Juni 2008 |
Helsingborg, Sweden, June 27, 2008 – DuoCort Pharma AB, a privately held Swedish drug development company, today announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation for the company’s DuoCort™ hydrocortisone dual-release oral tablet in development for the treatment of adrenal insufficiency – the inability of the body to produce sufficient amounts of the essential hormone cortisol.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 Next > End >>
|
| Results 1 - 10 of 15 |
